126 related articles for article (PubMed ID: 20136784)
21. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
[TBL] [Abstract][Full Text] [Related]
22. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
24. mTOR inhibitor-associated dermatologic and mucosal problems.
Campistol JM; de Fijter JW; Flechner SM; Langone A; Morelon E; Stockfleth E
Clin Transplant; 2010; 24(2):149-56. PubMed ID: 20236129
[TBL] [Abstract][Full Text] [Related]
25. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
[TBL] [Abstract][Full Text] [Related]
26. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
27. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
28. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
[TBL] [Abstract][Full Text] [Related]
29. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
30. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
Subbiah IM; Brown RE; Fallon MB
Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
[No Abstract] [Full Text] [Related]
31. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Kahan BD
Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
[TBL] [Abstract][Full Text] [Related]
32. [Indications of mTOR inhibitors in liver transplantation].
Calmus Y; Dharancy S
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S245-6. PubMed ID: 20004329
[No Abstract] [Full Text] [Related]
33. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
[TBL] [Abstract][Full Text] [Related]
34. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
35. Current immunosuppressive treatment after kidney transplantation.
Kho M; Cransberg K; Weimar W; van Gelder T
Expert Opin Pharmacother; 2011 Jun; 12(8):1217-31. PubMed ID: 21284571
[TBL] [Abstract][Full Text] [Related]
36. Resolved: in minimizing kidney transplant immunosuppression, steroids should go before calcineurin inhibitors: pro.
Matas AJ
J Am Soc Nephrol; 2007 Dec; 18(12):3026-8. PubMed ID: 18003783
[TBL] [Abstract][Full Text] [Related]
37. Resolved: in minimizing kidney transplant immunosuppression, steroids should go before calcineurin inhibitors: con.
Pavlakis M
J Am Soc Nephrol; 2007 Dec; 18(12):3028-30. PubMed ID: 18046783
[No Abstract] [Full Text] [Related]
38. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
Ji J; Zheng PS
Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression?
Soll C; Clavien PA
Hepatology; 2010 Apr; 51(4):1113-5. PubMed ID: 20373365
[No Abstract] [Full Text] [Related]
40. Reviewing the evidence for de novo immunosuppression with sirolimus.
Flechner SM
Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
